Novo Nordisk A/S (NVO)
System-Specific Biopharmaceuticals · $37.82 ▼ −2.7%
Acquirer's Multiple7.3×8th percentile of US stocks (lower is cheaper)
Rank in the screen#23of 30 in Large Cap 1000, cheapest first
FCF yield4.1%Free cash flow ÷ market cap
Shareholder yield5.7%4.8% dividends · 0.9% buybacks
Novo Nordisk sells obesity and diabetes drugs. Over five years its shares fell 23.9% while peers rose 232.1% and the S&P 500 rose 73.4%. …
Sign up free to read the full analysis of NVO
NVO is in the free Large Cap 1000 screen. A free account shows the full analysis, the value-trap check and its tear sheet.
It's free: just your email. You'll also get our newsletter, and can unsubscribe anytime. Already have an account? Log in